Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tango Clear all
Completed Not applicable Interventional Results available

Tango for Neuropathy Among Breast Cancer Survivors

NCT05114005
View directory record Official record
Conditions
Cancer, Breast, Neuropathy
Interventions
Rhythmic Auditory Stimulation, Evidence-Based Exercise
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Mitigation of Major Hip Injury Due to Fall With a Smart Belt

NCT05245097
View directory record Official record
Conditions
Hip Injuries, Fractures, Hip, Fall Injury, Fall Risk, Osteoporosis, Osteoporosis Risk
Interventions
Tango Belt, Standard of Care (SOC)
Device · Other
Lead sponsor
ActiveProtective Technologies, Inc
Industry
Eligibility
65 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Sacramento, California • Bensalem, Pennsylvania • Gwynedd, Pennsylvania + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional

Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

NCT06088355
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders, Neurodegeneration
Interventions
HV-PDAE: High Volume Partnered Dance Aerobic Exercise, MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise, MV-WALK: Moderate Volume Walking, HV-WALK: High Volume Walking
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms

NCT01768832
View directory record Official record
Conditions
Parkinson Disease
Interventions
Treadmill, Tango, Stretching
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Not applicable Interventional

Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease

NCT04122690
View directory record Official record
Conditions
Parkinson's Disease, Exercise Therapy, Cognition
Interventions
PDAE, WAE
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Tango for Alzheimer's Disease Patients' Caregivers

NCT03269149
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Adapted Tango Dance, Educational lectures
Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

NCT06810544
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Interventions
TNG456, abemaciclib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Motor Training in PD

NCT02457832
View directory record Official record
Conditions
Parkinson Disease
Interventions
Adapted Tango Dancing, Behavioral Control (BC) Condition
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
TNG908
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

NCT03446573
View directory record Official record
Conditions
HIV Infections
Interventions
DTG + 3TC, TAF based regimen (TBR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
54
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

NCT04489771
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Miami, Florida • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Not listed Phase 2 Interventional

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

NCT02908035
View directory record Official record
Conditions
Chronic Limb Ischemia
Interventions
Temsirolimus, Saline
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Everolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional

Tdcs And cogNitive traininG cOmbined for AUD (TANGO)

NCT05062369
View directory record Official record
Conditions
Alcohol Use Disorder, Addiction
Interventions
TaskFlow Transcranial Electrical Stimulation device, Executive Function Focused Cognitive Training
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Phase 2 Interventional

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

NCT06749210
View directory record Official record
Conditions
Cancer of the Breast, Chemotherapy-induced Neuropathy
Interventions
Tango
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
TNG462, Pembrolizumab
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2 Interventional

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

NCT01109121
View directory record Official record
Conditions
Moderate to Severe Gout, Hyperuricemia
Interventions
Combination 400, Allopurinol, Combination 600
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
La Jolla, California • Santa Maria, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2Phase 3 Interventional

PD4PD:Partnered Dance for Parkinson Disease

NCT01388556
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tango dancing
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 2, 2026, 10:29 PM EDT